Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Arecor Therapeutics PLC ( (GB:AREC) ) just unveiled an announcement.
Arecor Therapeutics plc, a Cambridge-based clinical-stage biotech listed on AIM, develops enhanced therapeutics for diabetes, obesity and other cardiometabolic conditions, led by AT278, an ultra-concentrated ultra-rapid insulin co-developed with Sequel Med Tech’s twiist automated insulin delivery system. The company is also building an oral peptide delivery platform, initially for GLP-1 receptor agonists, to further address the multi-billion-dollar cardiometabolic market.
The company announced it will publish full-year results for the 12 months to 31 December 2025 on 13 April 2026, alongside a webcast and Q&A for analysts and institutions that morning and a separate online presentation for private investors later in April. By staging dedicated briefings and making its results presentation available online, Arecor is signaling active investor engagement as it progresses its pipeline, with the upcoming figures likely to shed light on the advancement and commercial prospects of AT278 and its oral peptide platform.
The most recent analyst rating on (GB:AREC) stock is a Hold with a £84.00 price target. To see the full list of analyst forecasts on Arecor Therapeutics PLC stock, see the GB:AREC Stock Forecast page.
Spark’s Take on AREC Stock
According to Spark, TipRanks’ AI Analyst, AREC is a Neutral.
Arecor Therapeutics’ score is driven by positive corporate events, including strategic partnerships and IP expansion, which bolster its market position. However, financial performance challenges, such as ongoing losses and cash flow issues, weigh heavily on the overall score. Technical analysis and valuation present a neutral outlook, reflecting the typical risks and opportunities in the biotech sector.
To see Spark’s full report on AREC stock, click here.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a Cambridge, UK-based clinical-stage biotech company focused on developing improved therapeutics for diabetes, obesity and other cardiometabolic diseases. Its lead asset, AT278, is the only ultra-concentrated ultra-rapid-acting insulin in development and is being co-developed with Sequel Med Tech’s twiist automated insulin delivery system to target the large and growing diabetes market.
The company is also advancing a novel oral peptide delivery platform, initially targeting GLP-1 receptor agonists, as it seeks to reduce treatment burden and enhance outcomes for patients. Arecor is listed on London’s AIM market under the ticker AREC and leverages its proprietary formulation expertise, including its Arestat technology, to differentiate its pipeline in a competitive cardiometabolic therapeutics landscape.
Average Trading Volume: 15,731
Technical Sentiment Signal: Sell
Current Market Cap: £25.86M
See more insights into AREC stock on TipRanks’ Stock Analysis page.